Start of Year Update from CEO
Until 2023, Katalysen focused on developing early-stage Nordic tech companies, achieving two exits and building a portfolio of 24 promising companies. Among them, InvitePeople stands out as a rising industry leader.
In Q4 2024, InvitePeople declined a 100% acquisition bid, reinforcing our confidence in its future. The company continues to thrive, and has also initiated negotiations with potential strategic U.S. partners that would significantly extend its global reach. Having successfully entered the German market with clients like Deutsche Bahn, InvitePeople’s trajectory remains highly promising.
In late 2023, we intensified our focus on special situation investments, embracing our roots as an investment catalyst (more on this in the near future) and adding med-tech pioneers QuTEM and S4DX to our portfolio. These companies have already delivered substantial value, with our active involvement generating over SEK 200 M in value for stakeholders.
S4DX has rapidly scaled its innovative digital pre-analytical monitoring system, establishing partnerships with industry giants like Roche Diagnostics, Siemens, and BD (the worldwide leader in blood collection tubes). In late 2024, new strategic partnerships unlocked significant growth, and S4DX recently secured its first U.S. client, marking its entry into the world’s largest market. With revenue surging, 2025 is poised to be transformative.
QuTEM, the GMP-certified leader in electron microscopy services for life sciences, serves 9 of the world’s top 10 pharmaceutical companies. The company’s groundbreaking work supports the expanding gene therapy market, with 50% of its revenue now originating from the U.S. Following a restart just one year ago, the company has since 2024 Q4 achieved positive cash flow and is set for sustained growth.
By H2 2025, we anticipate that InvitePeople, S4DX, and QuTEM will hit revenue and profitability milestones, warranting significantly higher valuations. Beyond these three, we’ve identified 7-10 other portfolio companies with strong near-term potential. Several raised funds during 2024 Q4, and our active involvement ensures they’re well-positioned for value-maximizing exits, when the time is right.
Twelve months ago, we made the decision to maintain our financial position not through share issues, but through strategic small asset sales and similar measures. We have successfully upheld this strategy and continue to successfully service our financial position in this manner, supported by shareholders choosing to exercise existing warrants on Katalysen shares, as well as small strategic asset sales and other related measures.
This strategy is in place while we continue to develop the above leads (InvitePeople, QuTEM, S4DX, and the rest of the portfolio) towards exits at the right price. While challenges lie ahead, our mission is clear: to deliver sustained value for our shareholders. The strength of our existing portfolio, combined with the new transactions we aim to finalize in the next six months, makes 2025 an incredibly exciting year for Katalysen. I’m deeply grateful to our shareholders, partners, and co-investors for being part of this journey.
Yours Sincerely,
Peter Almberg,
CEO, Katalysen
For more information on Katalysen, please contact:
CEO Peter Almberg
Phone: +46 76 860 37 00
E-mail: contact@katalysen.com
Web: www.katalysen.com
About Katalysen: Katalysen is an investment catalyst, combining our expertise and capital with that of our partners to help owner-led companies and investors turn special situation challenges into opportunities for long-term value creation. We are defined by a highly collaborative approach, a focus on transformative special situations, and bespoke investment structures that ensure alignment of interests for all stakeholders. Since our founding in 2016, we have built a portfolio of 26 dynamic companies, with a primary focus on B2B technology providers. With offices in Stockholm and Geneva, Katalysen has been publicly listed since 2022.